| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
This compound is a chemical reagent and building block; it does not have a direct biological target. Its function is to serve as a substrate in the solid-phase chemical synthesis of RNA molecules.
|
|---|---|
| ln Vitro |
This compound is not a drug; it is a chemical reagent. Its "activity" is chemical, not biological. It is highly efficient in solid-phase RNA synthesis, enabling the incorporation of cytidine into growing RNA chains with high stepwise coupling yields (typically >98%), which is crucial for the production of long and pure RNA sequences.
|
| ln Vivo |
This compound is a reagent used for in vitro synthesis and is not designed for in vivo activity. Its application is strictly biochemical, performed outside a living organism. Therefore, no in vivo activity is applicable.
|
| Enzyme Assay |
Not applicable. As a protected nucleoside for chemical synthesis, it is not involved in receptor binding assays. The "quality control" for this building block involves chromatographic methods (e.g., UPLC) to confirm purity. An assay to confirm its identity would be LC-MS (Liquid Chromatography-Mass Spectrometry), which measures the exact mass of the molecule to ensure it is the correct DMT-protected ribonucleoside.
|
| Cell Assay |
Not applicable. This compound is not used in cell-based bioactivity assays. Its performance is evaluated in chemical synthesis protocols. A standard test is its "coupling efficiency" in a DNA/RNA synthesizer, where the release of the DMT cation is measured spectrophotometrically. Higher DMT release indicates more efficient incorporation of the amidite into the growing oligonucleotide chain.
|
| Animal Protocol |
Not applicable. As a chemical building block, it is used in automated synthesizers, not administered to animals. Therefore, no in vivo animal experimental protocols apply to this reagent.
|
| ADME/Pharmacokinetics |
Not applicable. As a chemical for in vitro synthesis, pharmacokinetic properties (absorption, distribution, metabolism, excretion) are irrelevant for its use. Its chemical stability under standard storage and synthesis conditions (e.g., in anhydrous acetonitrile) is the more relevant property.
|
| Toxicity/Toxicokinetics |
Not applicable. This chemical is not administered to living systems for its intended purpose, so its toxicological profile is not applicable. Standard laboratory safety precautions for handling chemical powders and their solutions in organic solvents are always followed.
|
| Additional Infomation |
This product is a standard RNA phosphoramidite, a fundamental tool in molecular biology. The DMT group is an acid-labile protecting group, removed during synthesis to allow further chain extension. The Bz group is a base-labile protecting group, removed at the end of synthesis. It is strictly for research and development purposes and is not a pharmaceutical product.
|
| Molecular Formula |
C37H35N3O8
|
|---|---|
| Molecular Weight |
649.69
|
| Exact Mass |
649.242
|
| CAS # |
81246-76-6
|
| PubChem CID |
13168511
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
132-135°C
|
| LogP |
4.213
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
48
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)OC)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=CC(=NC5=O)NC(=O)C6=CC=CC=C6)O)O
|
| InChi Key |
KCLOEKUQZJAMFG-NHASGABXSA-N
|
| InChi Code |
InChI=1S/C37H35N3O8/c1-45-28-17-13-26(14-18-28)37(25-11-7-4-8-12-25,27-15-19-29(46-2)20-16-27)47-23-30-32(41)33(42)35(48-30)40-22-21-31(39-36(40)44)38-34(43)24-9-5-3-6-10-24/h3-22,30,32-33,35,41-42H,23H2,1-2H3,(H,38,39,43,44)/t30-,32-,33-,35-/m1/s1
|
| Chemical Name |
N-[1-[(2R,3R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3,4-dihydroxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (153.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.85 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.85 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5392 mL | 7.6960 mL | 15.3920 mL | |
| 5 mM | 0.3078 mL | 1.5392 mL | 3.0784 mL | |
| 10 mM | 0.1539 mL | 0.7696 mL | 1.5392 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
